Skip to Content

Retired Forms Manuals

Main Content

For reference purposes, CIBMTR provides online access to manuals for retired CIBMTR and NMDP forms, Response Criteria documents, and Appendices. See the sections below for all retired content.   

Retired Forms Manuals

Form Number Form Name Form Version Retired Date
2000 Baseline Form Instructions (PDF) ​5.0 October 2020
2000 Baseline Form Instructions (PDF) 4.0 ​January 2020
2000 ​Baseline Form Instructions (PDF) 4.0 March 2015
2000 Baseline Form Instructions (PDF) 3.0 ​October 2013
2003 Gene Therapy Product Form Instructions (PDF) 1.0 July 2024
2004 ​Infectious Disease Markers Form Instructions (PDF) 5.0 ​September 2022
2004 Infectious Disease Markers Form Instructions (PDF) ​4.0 January 2020
2004 Infectious Disease Markers Form Instructions (PDF) 4.0 March 2015
2004 Infectious Disease Markers Form Instructions (PDF) ​3.0 ​October 2013
2005 ​Confirmation of HLA Typing Form Instructions (PDF) ​7.0 September 2022
2005 Confirmation of HLA Typing Form Instructions (PDF) 6.0 ​January 2020
2005 Confirmation of HLA Typing Form Instructions (PDF) 5.0 January 2017
2005 Confirmation of HLA Typing Form Instructions (PDF) 4.0 October 2013
2006 ​Infusion Form Instructions (PDF) 5.0 September 2022
2006 Infusion Form Instructions (PDF) 4.0 January 2020
2006 ​Infusion Form Instructions (PDF) 4.0 March 2015
2006 Infusion Form Instructions (PDF) 2.0 October 2013
2006 Infusion Form FAQ (PDF)​ 1.0​ February 2010
​2010 ​Acute Myelogenous Leukemia (AML) Pre-HCT Data Form Instructions (PDF) 3.0 July 2017
​2010 Acute Myelogenous Leukemia (AML) Pre-HSCT Data Form Instructions (PDF) 2.0 October 2013
2011 Acute Lymphoblastic Leukemia (ALL) Pre-HCT Data Form Instructions (PDF) ​4.0 July 2017
2013 Chronic Lymphocytic Leukemia (CLL) Pre-HCT Data Form Instructions (PDF) 2.0 March 2015
​2014 ​Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data Form Instructions (PDF) ​3.0 ​May 2020
​2014 Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data Form Instructions (PDF) 2.0 March 2015
2015 ​Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data Form Instructions (PDF) 3.0 March 2015
​2016 Multiple Myeloma / Plasma Cell Disorders (PCD) Pre-HCT Data Form Instructions (PDF) ​3.0 ​April 2021
​2016 ​Multiple Myeloma / Plasma Cell Disorders (PCD) Pre-HCT Data Form Instructions (PDF) ​3.0 January 2020
​2016 Multiple Myeloma / Plasma Cell Disorders (PCD) Pre-HCT Data Form Instructions (PDF) ​3.0 March 2015
​2016 Multiple Myeloma / Plasma Cell Disorders (PCD) Pre-HCT Data Form Instructions (PDF) 2.0 October 2013
2018 Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data Form Instructions (PDF) 4.0 January 2019
2018 ​Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data Form Instructions (PDF) 5.0 October 2020
2018 Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data Form Instructions (PDF) ​3.0 January 2018
2018 Hodgkin and Non-Hodgkin Lymphoma Pre-HSCT Data Form Instructions (PDF) ​2.0 October 2013
2019 Waldenstrom's Macroglobulinemia / Lymphoplasmacytic Lymphoma (MAC) Pre-HCT Data Form Instructions (PDF) 3.0 March 2015
2028 Aplastic Anemia Pre-HCT Data Form Instructions (PDF) 2.0 October 2020
2028 Aplastic Anemia Pre-HCT Data Form Instructions (PDF) 1.0 March 2015
2034 X-Linked Lymphoproliferative Syndrome (XLP) Pre-HCT Data Form Instructions ​3.0 March 2015
2037 Leukodystrophies Pre-Infusion Form Instructions (PDF) 3.0 July 2024
2039 Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data Form Instructions (PDF) ​3.0 March 2015
​2046 ​Fungal Infection Pre-Infusion Data (PDF) ​4.0 May 2018
2058 Thalassemia Pre-Infusion Form Instructions (PDF) 1.0 July 2024
2100 Post-HCT Follow-Up (PDF) 8.0 October 2023
2100 Post-HCT Follow-Up (PDF) ​7.0 September 2022
2100 Post-HCT Follow-Up (PDF) 6.0 July 2021
2100 100 Day Post-HCT Data Form Instructions (PDF)​ ​5.0 October 2020
2100 100 Day Post-HCT Data Form Instructions (PDF) 4.0 ​July 2018
2100 100 Days Post-HCT Data Form Instructions (PDF) ​3.0 January 2017
2110 ​Acute Myelogeneous Leukemia (AML) Post-HCT Data Form Instructions (PDF) ​3.0 July 2017
2110 Acute Myelogenous Leukemia (AML) Post-HSCT Data Form Instructions (PDF) ​2.0 ​October 2013
​2111 ​Acute Lymphoblastic Leukemia (ALL) Post-HCT Data Form Instructions (PDF) ​3.0 July 2017
2113 Chronic Lymphocytic Leukemia (CLL) Post-HCT Data Form Instructions (PDF) ​2.0 ​March 2015
2114 Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data Form Instructions (PDF) 3.0 May 2020
2114 Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data Form Instructions (PDF) 2.0 ​March 2015
​2115 ​Juvenile Myelomonocytic Leukemia (JMML) Post-HCT Data Form Instructions (PDF) 3.0 ​March 2015
​2116 Multiple Myeloma / Plasma Cell Disorders (PCD) Post-HCT Data Form Instructions (PDF) 3.0 April 2021
​2116 Multiple Myeloma / Plasma Cell Disorders (PCD) Post-HCT Data Form Instructions (PDF) 3.0 ​January 2020
​2116 Multiple Myeloma / Plasma Cell Disorders (PCD) Post-HCT Data Form Instructions (PDF) 3.0 March 2015
​2116 Multiple Myeloma / Plasma Cell Leukemia Post-HSCT Data Form Instructions (PDF) ​2.0 ​October 2013
​2118 Hodgkin and Non-Hodgkin Lymphoma Post-HCT Data Form Instructions (PDF) ​3.0 January 2018
​2118 Hodgkin and Non-Hodgkin Lymphoma Post-HCT Data Form Instructions (PDF) 2.0 October 2013
2119 Waldenstrom's Macroglobulinemia / Lymphoplasmacytic Lymphoma (MAC) Post-HCT Data Form Instructions (PDF) 3.0 March 2015
2128 Aplastic Anemia Post-HCT Data Form Instructions (PDF) 2.0 October 2020
2128 Aplastic Anemia Post-HCT Data Form Instructions (PDF) 1.0 March 2015
2134 X-Linked Lymphoproliferative Syndrome (XLP) Post-HCT Data Form Instructions (PDF) 3.0 March 2015
2137 Leukodystrophies Post-Infusion Form Instructions (PDF) 3.0 July 2024
2139 Hemophagocytic Lymphohistiocytosis (HLH) Post-HCT Data Form Instructions (PDF) ​3.0 March 2015
2146 Fungal Infection Post-Infusion Data (PDF) ​3.0 ​May 2018
2158 Thalassemia Post-Infusion Form Instructions (PDF) 1.0 July 2024
​2200 ​Six Months to Two Years Post-HCT Data Form Instructions (PDF) ​3.0 ​January 2017
2300 Greater Than Two Years Post-HCT Data Form Instructions (PDF) ​3.0 ​January 2017
2400 Pre-TED Form Instructions (PDF) ​9.0 September 2022
2400 Pre-TED Form Instructions (PDF) 8.0 October 2021
2400 Pre-TED Form Instructions (PDF) 7.0 January 2021
2400 Pre-TED Form Instructions (PDF) 6.0 May 2020
2400 Pre-TED Form Instructions (PDF) 5.0 January 2020
2400 Pre-TED Form Instructions (PDF) ​4.0 January 2017
2400 Pre-TED Form Instructions (PDF) ​3.0 October 2013
2402 Pre-TED Disease Classification Form Instructions (PDF) 7.0 April 2024
2402 ​Pre-TED Disease Classification Form Instructions (PDF) 6.0 September 2022
2402 ​Pre-TED Disease Classification Form Instructions (PDF) 5.0 October 2020
2402 Pre-TED Disease Classification Form Instructions (PDF) 4.0 May 2020
2402 Pre-TED Disease Classification Form Instructions (PDF) 3.0 ​January 2020
2402 Pre-TED Disease Classification Form Instructions (PDF) 2.0 ​January 2018
2402 Pre-TED Disease Classification Form Instructions (PDF) 1.0 ​July 2017
2450 Post-TED Form Instructions (PDF) 7.0 July 2024
2450 Post-TED Form Instructions (PDF) 6.0 ​September 2022
2450 Post-TED Form Instructions (PDF) ​5.0 October 2021​
2450 Post-TED Form Instructions (PDF) 4.0 January 2020
2450 Post-TED Form Instructions (PDF) ​3.0 ​January 2017
2540 Tepadina® Supplemental Data Collection Form Instructions (PDF) 1.0 April 2019
2542 Mogamulizumab Supplemental Data Collection (PDF) 1.0 January 2024
​2556 Myelofibrosis Pre-HCT Data 1.0 May 2020
2557 Myelofibrosis Post-HCT Data 1.0 May 2020
2800 ​Log of Appended Documents Form Instructions (PDF) 2.0 March 2015
​General Instructions Section 11 Log of Appended Documents N/A August 2014
2804 CIBMTR Recipient ID Assignment Form Instructions (PDF) 5.0 October 2019
2804 CIBMTR Recipient ID Assignment Form Instructions (PDF) ​4.0 March 2015
2814 Indictation Form Instructions (PDF) 4.0 July 2024
2814 ​Indication Form Instructions (PDF) ​2.0 ​April 2019
2900 Recipient Death Data Form Instructions (PDF) 4.0 ​October 2021
2900 Recipient Death Data Form Instructions (PDF) ​3.0 ​January 2019
2900 Recipient Death Data Form Instructions (PDF) 2.0 January 2017
2900 Recipient Death Data Form Instructions (PDF) 1.0 ​March 2015
3500 Subsequent Neoplasms (PDF) 1.0 ​July 2021
4000 Cellular Therapy Essential Data Pre-Infusion Form Instructions (PDF) 9.0 July 2023
4000 Cellular Therapy Essential Data Pre-Infusion Form Instructions (PDF) 8.0 September 2022
4000 Cellular Therapy Essential Data Pre-Infusion Form Instructions (PDF) 7.0 ​July 2021
4000 Cellular Therapy Essential Data Pre-Infusion Form Instructions (PDF) 6.0 ​January 2021
4000 Cellular Therapy Essential Data Pre-Infusion Form Instructions (PDF) ​5.0 ​January 2020
4000 Cellular Therapy Essential Data Pre-Infusion Form Instructions (PDF) 4.0 January 2018
4000 Cellular Therapy Essential Data Pre-Infusion Form Instructions (PDF) ​3.0 July 2017
4003 Cellular Therapy Product Form Instructions (PDF) 5.0 July 2023
4003 Cellular Therapy Product Form Instructions (PDF) 4.0 February 2022​
4003 Cellular Therapy Product Form Instructions (PDF) 3.0 January 2021
4003 Cellular Therapy Product Form Instructions (PDF) 2.0 January 2020
4003 ​Cellular Therapy Product Form Instructions (PDF) 1.0 ​January 2019
4006 Cellular Therapy Infusion Data Form Instructions (PDF) 6.0 July 2023
4006 Cellular Therapy Infusion Data Form Instructions (PDF) 5.0 February 2022
4006 Cellular Therapy Infusion Data Form Instructions (PDF) 4.0 ​January 2021
4006 Cellular Therapy Infusion Data Form Instructions (PDF) 3.0 ​January 2020
4006 Cellular Therapy Infusion Data Form Instructions (PDF) 2.0 January 2018
4006 Cellular Therapy Infusion Data Form Instructions (PDF) 1.0 ​July 2017
4100 Cellular Therapy Essential Data Follow-Up Form Instructions (PDF) 8.0 July 2023
​4100 Cellular Therapy Essential Data Follow-Up Form Instructions (PDF) 7.0 ​February 2022
​4100 Cellular Therapy Essential Data Follow-Up Form Instructions (PDF) ​6.0 July 2021
​4100 Cellular Therapy Essential Data Follow-Up Form Instructions (PDF) ​5.0 ​January 2021
​4100 Cellular Therapy Essential Data Follow-Up Form Instructions (PDF) 4.0 January 2020
​4100 Cellular Therapy Essential Data Follow-Up Form Instructions (PDF) 3.0 October 2018
​4100 Cellular Therapy Essential Data Follow-Up Form Instructions (PDF) ​2.0 January 2018
​4100 Cellular Therapy Essential Data Follow-Up Form Instructions (PDF) 1.0 July 2017
N/A​

Supplemental Report Form Manuals

N/A​ ​September 2013
N/A​ TED Manual (PDF) N/A​ ​January 2008
N/A​ NMDP Forms Instruction Manual (PDF) N/A​ December 2007
N/A​ CIBMTR Data Management Manual (PDF) N/A​ December 2007
N/A​ CIBMTR Registration Instruction Manual (PDF) N/A​ December 2007

 

Appendices

Appendix Letter Appendix Name
Table of Contents (PDF) Appendices Table of Contents
Appendix A (PDF) Abbreviations and Definitions
Appendix B (PDF) Glossary of Terms
Appendix C (PDF) ​Cytogenetic Assessments
Appendix C (PDF) CIBMTR Data Collection Forms
Appendix D (PDF) How to Distinguish Infusion Types
Appendix D (PDF) Unique ID Assignment Form (CRID), Form 2804
Appendix E (PDF) Public Health Authority (PHA) Status
Appendix F (PDF) Validation Ranges
Appendix G (PDF) Continuous Process Improvement (CPI) and Procedures for Non-Compliance
Appendix H (PDF) Summary of CIBMTR On-Site Data Audit Program
Appendix H (PDF) MDS & MPN Subtypes
Appendix I (PDF) Ethnicity and Race
Appendix J (PDF) Reporting Comorbidities 
Appendix K (PDF) Key Fields
Appendix L (PDF) Karnofsky/Lansky Performance Status
Appendix M (PDF) The Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI)
Appendix M (PDF) HCT Critical Data Fields 
Appendix N (PDF) Response Evaluation Criteria in Solid Tumors (RECIST)
Appendix O (PDF) How to Distinguish Infusion Types
Appendix O (PDF) Cellular Therapy Critical Fields
Appendix P (PDF) Definition of Product
Appendix Q (PDF) United States Abbreviations
Appendix R (PDF) ​Cytogenetic Abbreviations and Terminology
Appendix S (PDF) Multiple Donor Chimerism
Appendix T (PDF) Pre-HCT Treatment for Lymphoma
Appendix U (PDF) Helpful Hints for Reporting Co-Existing Diseases​
Appendix V (PDF) Multiple Myeloma - Defining What Baseline to Use When Determining the Best Response to HSCT
Appendix W (DOC) Tracking Disease Status for Multiple Myeloma
Appendix Y (PDF) Critical Fields
Appendix Z (PDF) Primary Disease and Disease Inserts Due